Dova Pharmaceuticals Inc.
DOVA evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Lead Asset:
- doptelet (Phase 3)
What it means
What to watch
Prepared research question
What matters most for DOVA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
doptelet (Phase 3)
Next Catalyst
—
Tracking 1 pipeline candidate for Dova Pharmaceuticals Inc..
Run Dova Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Dova Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Dova Pharmaceuticals Inc.'s lead drug candidate?
Dova Pharmaceuticals Inc.'s most advanced tracked candidate is doptelet (Phase 3) for Chemotherapy-induced thrombocytopenia (CIT).
Who is the CEO of Dova Pharmaceuticals Inc.?
United Therapeutics Corporation is the chief executive officer of Dova Pharmaceuticals Inc. (DOVA).
What therapeutic areas does Dova Pharmaceuticals Inc. focus on?
Dova Pharmaceuticals Inc. develops therapies across Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.